lumateperone (Caplyta) Report issue

Small molecule Approved FDA Fast Track FDA
DrugBank

Active Ingredient History

NOW
  • Now
Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the butyrophenone class. It is approved for the treatment of schizophrenia as well as bipolar depression, as either monotherapy or adjunctive therapy. It is developed by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb. Lumateperone was approved for medical use in the United States in December 2019 with an initial indication for schizophrenia, and became available in February 2020. It has since demonstrated efficacy in bipolar depression and received FDA approval in December 2021 for depressive episodes associated with both bipolar I and II disorders.   Wikipedia

Chemistry

  • SMILES: CN1CCN2c3c(cccc31)[C@@H]1CN(CCCC(=O)c3ccc(F)cc3)CC[C@@H]12.Cc1ccc(S(=O)(=O)O)cc1
  • InChIKey: LHAPOGAFBLSJJQ-GUTACTQSSA-N
  • Mol. Mass: 565.71
  • ALogP: 3.92
  • ChEMBL Molecule:
    lumateperone tosylate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$32.7513 - $44.6003
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

lumateperone

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (1)


 

Schizophrenia (approved 2019)

Experimental Indications - Clinical Trial Phases 1-4 (7)


 

Acne Vulgaris (Phase 1)

Bipolar Disorder (Phase 3)

Borderline Personality Disorder (Phase 2)

Depressive Disorder, Major (Phase 3)

Healthy Volunteers (Phase 1)

Psychotic Disorders (Phase 4)

Schizophrenia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue